In this episode of BioTalk, Jeff Galvin, CEO & Founder of American Gene Technologies (AGT) joins host Rich Bendis to discuss genetic medicines, funding strategies, company goals, and the BioHealth Capital Region. 

Jeff earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies. In 2007, he met Dr. Roscoe Brady, an accomplished research scientist at National Institute of Neurological Disorders and Stroke (NINDS) and founded American Gene Technologies with the mission to transform peoples’ lives with genetic medicines. Jeff Galvin’s current focus is to grow AGT and he expects AGT’s patented, lead candidate for an HIV Cure to enter the clinic in 2019. AGT is a gene and cell therapeutics company with a proprietary lentiviral platform targeting major diseases, including HIV, Phenylketonuria (PKU) and cancer. The company has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine. AGT’s immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers has recently been awarded four patents. In collaboration with Stanford Medical School’s Dr. Dean Felsher, this novel approach to stimulate the body’s immune system to attack solid cancer tumors is showing promising results in animal models and is expected to enter human trials in the next 24 months.

Listen now on iTunes Google Play , and TuneIn

biotalk-angela-graham-quality-biological-image.jpg

Angela Graham, President and CEO of Quality Biological, Inc. (QBI), joins BioTalk host Rich Bendis to discuss growing a business in the Life Sciences Community, her involvement in the BHCR, and recruiting top talent in this region. Angela Graham, President and CEO of Quality Biological, Inc. (QBI), joins BioTalk host Rich Bendis to discuss growing a business in the Life Sciences Community, her involvement in the BHCR, and recruiting top talent in this region.

Angela has been in this industry for decades working for Bristol-Myers Squibb, Pfizer and UCB Pharma before taking over QBI. Her background and expertise is ideally suited to lead the company’s diversification from a leading government contractor into one which also supports the diverse R&D needs of the biopharmaceutical space.

Google Play, iTunes, TuneIn and on the website.

biotalk-Rip-Ballou-gsk-image.jpg

In this new episode of BioTalk, Rip Ballou, MD, VP & Head, GSK Global Vaccines US R&D Center and BHI President & CEO Rich Bendis discuss GSK’s move to the BioHealth Capital Region, their Vaccines Portfolio/Future, and the importance of succeeding in the industry today.

W. Ripley Ballou, MD is Vice President and Head, GSK Global Vaccines U.S. R&D Center in Rockville, MD - Just outside of Washington, DC. Prior to this he was VP and Head, Clinical Research and Translational Science, Vaccine Discovery and Development at GSK Vaccines in Rixensart, Belgium. Previously he served as Deputy Director for Vaccines, Infectious Diseases Development, Global Health at the Bill & Melinda Gates Foundation. Dr. Ballou is an expert in vaccine development and has worked in this field for more than 30 years. Trained in Internal Medicine and Infectious Diseases, he began his work on vaccines at the Walter Reed Army Institute of Research where he led the team that with GlaxoSmithKline co-developed RTS,S, the world’s most advanced malaria vaccine. Dr. Ballou has numerous publications in the field of vaccine development and infectious diseases.

Listen now on iTunes Google Play , and TuneIn

BioTalk Podcast brady scheer

In this new episode of BioTalk, Matt Brady and BHI President & CEO Rich Bendis discuss topics around lab spaces in the area including, availability, shortages, and solutions to create more in the BioHealth Capital Region.In this new episode of BioTalk, Matt Brady and BHI President & CEO Rich Bendis discuss topics around lab spaces in the area including, availability, shortages, and solutions to create more in the BioHealth Capital Region.

Since joining Scheer Partners in 2003, Matt Brady has successfully completed commercial real estate transactions for more than 500,000 square feet of office, R&D and industrial space totaling close to $100 million in transaction value.

Listen now on iTunes Google Play , and TuneIn

BioTalk Podcast anderson deloitte

Margaret Anderson, Managing Director at Deloitte Consulting LLP, sits down with host Rich Bendis for this episode of BioTalk. They discuss her career path, putting patients at the center of biomedical and public health, and engaging with all sectors. Margaret Anderson is a Managing Director at Deloitte Consulting LLP focused on using strategy to make organizations, agencies, and programs stronger and more laser focused on outcomes for patients. Her career has traversed biomedical and public health policy and she’s motivated by the change she’s seen in bringing treatments and solutions for patients forward.

As used in this podcast, “Deloitte” means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of our legal structure. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Listen now on iTunes Google Play , and TuneIn

/bhcr-pt-1-biotalk-podcast.jpg

In this second part of two episodes, Rich sits down with leaders from different parts of the BHCR to talk about what they are working on, and their thoughts on the event. His guests are Todd Haim, SBIR Director, NCI SBIR Development Center at NIH, and Matthew McMahon, Director, Office of Translational Alliances and Coordination at the National Heart, Lung, and Blood Institute at NIH

Listen now on iTunes Google Play , and TuneIn

/bhcr-pt-1-biotalk-podcast.jpg

In this first part of two episodes, Rich sits down with leaders from different parts of the BHCR to talk about what they are working on, and their thoughts on the event. His guests are Jim Jackson, SVP, CSO at Emergent BioSolutions and Jim Hughes, Vice President at University of Maryland, Baltimore.

Listen now on iTunes Google Play , and TuneIn

wyskiel-biotalk-image.jpg

Christy Wyskiel, an investor, entrepreneur, and ecosystem builder, serves as Senior Advisor to President Daniels at Johns Hopkins University. She runs the group Johns Hopkins Technology Ventures, which serves as the tech transfer, corporate partnership, and start-up arm of the university. In this episode of BioTalk, Christy and Rich discuss Tech Transfer, Innovation, Investment, Partnerships, Collaborations, and other important areas that she and JHU work on every day.

Listen now on iTunes Google Play , and TuneIn

Biotalk qi image

Lily, Qi, Assistant Chief Administrative Officer – Office of Montgomery County Executive joins Rich for this episode of BioTalk. They discuss the topics like the role that MoCo plays in Economic Development, Cultural Competence in a diverse region, and her future career goals. Lily has served County Executive Ike Leggett for eight years in various capacities and led strategic initiatives including privatizing economic development functions; establishing BioHealth Innovation, Inc. to advance research commercialization; developing global partnerships; improving nighttime economy, and developing the Comprehensive Economic Strategy. Lily joined Montgomery County after serving as Vice President of Business Development and Marketing for the Washington, DC Economic Partnership and spokesperson for the DC Department of Insurance, Securities and Banking.

Listen now on iTunes Google Play , and TuneIn

petr-mcedc-biotalk-image

This discussion covers how David arrived in Maryland, the role of MCEDC in the BioHealth Capital Region, and why Montgomery County is a great place to do business.

Before becoming the inaugural President and CEO of MCEDC, David was with the Central Florida Development Council, where as President and CEO, he achieved record-setting job creation and capital investment results. Previously, David was the Executive Director of the Winter Haven Economic Development Council in Florida. In Texas, he has held key marketing management positions in economic development and was an advertising agency owner in Austin.

Listen now on iTunes Google Play , and TuneIn

Bio talk rachel king image

Rachel K. King, Co-Founder and CEO, GlycoMimetics, Inc. (GMI), joins Rich Bendis for the latest episode of BioTalk. They cover topics from her background in the industry to running a publicly traded company in the BioHealth Capital Region. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms.  Mrs. King came to NEA after serving as a Senior Vice President of Novartis Corporation. She also served as Chairman of International BIO.

Listen now on iTunes Google Play , and TuneIn

Perman umd biotalk image

Dr. Jay Perman, President, University of Maryland, Baltimore, joins Rich Bendis for a BioHealth Capital Region conversation. They cover topics from Innovation and Commercialization to Community and Education in the region. Dr. Perman is the sixth President of the University of Maryland, Baltimore. His presidency is marked by a commitment to such issues as interprofessional education, community engagement, innovation and commercialization, and economic development.

Listen now on iTunes Google Play , and TuneIn

biotalk-john-cohen-image.jpg

Johnathan Cohen., Founder, and Chief Executive Officer, 20/20 GeneSystems Inc. joins Rich Bendis to discuss cancer diagnostics, crowdfunding, and where his company is headed. Under Mr. Cohen’s leadership, 20/20 GeneSystems has brought in approximately $7.5 million in grant funding and launched two successful products, a kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for the early detection of lung cancer.

Listen now on iTunes Google Play , and TuneIn

biotalk-kurt-newman-image

Kurt Newman, M.D., President and Chief Executive Officer, Children’s National Health System joins Rich Bendis to discuss quality of care, medical innovation, and the future of healthcare. Since 1984, Dr. Newman has gone from Surgical Fellow to President and CEO at Children’s. He has championed innovations in the health system for both physical and mental health.

Listen now on iTunes Google Play , and TuneIn